Fast Facts: Measurable Residual Disease PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Fast Facts: Measurable Residual Disease PDF full book. Access full book title Fast Facts: Measurable Residual Disease by J. Loke. Download full books in PDF and EPUB format.
Author: J. Loke
Publisher: Karger Medical and Scientific Publishers
ISBN: 331806825X
Category : Medical
Languages : en
Pages : 33
Get Book Here
Book Description
Conventional methods of detecting disease remission in cancers such as leukemia rely on microscopic analysis of tissue samples. Measurable (or minimal) residual disease (MRD) describes the presence of disease beyond the levels of sensitivity afforded by microscopy. Fast Facts: Measurable Residual Disease describes what is meant by MRD, the opportunities and challenges afforded by its identification and the advantages and disadvantages of the methods used for its detection. Specific examples are given to illustrate the implications of detecting MRD in different disease scenarios, with emphasis on acute myeloid and lymphoblastic leukemias. With the recognition and monitoring of MRD likely to play an increasingly important role in disease prognosis and subsequent treatment direction, this accessible resource is ideal for any healthcare professional wanting to know more about this exciting and fast-moving area. Table of Contents: • What is measurable residual disease? • How is MRD measured? • What is the significance of MRD?
Author: J. Loke
Publisher: Karger Medical and Scientific Publishers
ISBN: 331806825X
Category : Medical
Languages : en
Pages : 33
Get Book Here
Book Description
Conventional methods of detecting disease remission in cancers such as leukemia rely on microscopic analysis of tissue samples. Measurable (or minimal) residual disease (MRD) describes the presence of disease beyond the levels of sensitivity afforded by microscopy. Fast Facts: Measurable Residual Disease describes what is meant by MRD, the opportunities and challenges afforded by its identification and the advantages and disadvantages of the methods used for its detection. Specific examples are given to illustrate the implications of detecting MRD in different disease scenarios, with emphasis on acute myeloid and lymphoblastic leukemias. With the recognition and monitoring of MRD likely to play an increasingly important role in disease prognosis and subsequent treatment direction, this accessible resource is ideal for any healthcare professional wanting to know more about this exciting and fast-moving area. Table of Contents: • What is measurable residual disease? • How is MRD measured? • What is the significance of MRD?
Author: William Blum
Publisher: Karger Medical and Scientific Publishers
ISBN: 1910797596
Category : Medical
Languages : en
Pages : 90
Get Book Here
Book Description
This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor prognosis for most patients with the disease. The new drugs reflect the remarkable progress that has been made in our understanding of the pathophysiology of AML and its underlying cytogenetic and molecular abnormalities - which differ not only between patients but also within a patient over time and with treatment. 'Fast Facts: Acute Myeloid Leukemia' provides a comprehensive yet concise foundation for understanding AML: from basic epidemiology, diagnosis, classification and the current 'standard' treatment, through to recent advances in our understanding of the cytogenetic and molecular underpinnings of the disease, such as the IDH2 mutation, and the future for tailored therapy. It will be useful to primary care providers, medical students, specialist nurses, junior doctors and allied healthcare professionals who want to develop a thorough grounding in our evolving understanding of AML and its treatment. Contents: • Epidemiology, pathophysiology and etiology • Diagnosis • Treatment • Supportive care • Prognosis and monitoring • Emerging treatments • Useful resources
Author: Donal McLornan
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318070807
Category : Medical
Languages : en
Pages : 102
Get Book Here
Book Description
Myelofibrosis is a myeloproliferative neoplasm that has markedly heterogeneous features. The clinical phenotype can range from initial indolent presentation, which may be stable for many years, through to marked cytopenias, debilitating constitutional symptoms, massive splenomegaly and an inherent risk of leukemic transformation. Despite many advances regarding molecular classification, prognostication models and rapeutic options over the last few decades, allogeneic stem cell transplantation remains the only curative option, yet is suitable only for a minority of patients. ‘Fast Facts: Myelofibrosis’ is written for health professionals by two leading experts in the field, and provides up-to-date guidance on its accurate diagnosis, risk stratification and management. It also provides key insights into the molecular biology underpinning the disease. This concise handbook is an indispensable read for anyone wanting to get up to speed with best practice in the diagnosis and care of people with myelofibrosis. Table of Contents: • Presentation, classification and epidemiology • Molecular biology and pathogenesis • Clinical assessment and diagnosis • Prognostic models • Treatment approaches • Allogeneic stem cell transplantation • Management of blast-phase myelofibrosis • Therapies in development
Author: T.A. Eyre
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318069744
Category : Medical
Languages : en
Pages : 74
Get Book Here
Book Description
Chronic lymphocytic leukemia (CLL) is the most diagnosed leukemia in the Western world, accounting for approximately 25% of all new leukemia diagnoses. In recent years, remarkable progress has been made in our understanding of both the pathophysiology and genetics of CLL. While the disease generally affects older adults and initially follows an indolent course, cytogenetic and molecular profiling have helped to predict clinical outcomes. Greater prognostication, alongside the development of an increasing armamentarium of novel targeted therapies, has enabled us to provide more personalized management options for patients. 'Fast Facts: Chronic Lymphocytic Leukemia' covers the epidemiology, etiology, diagnosis and staging of the disease, and the molecular and genetic aspects that underpin treatment and prognosis. It provides a concise overview of treatment options, in both the front-line and relapsed/refractory settings, with particular focus on the novel targeted agents that have overcome many adverse prognostic factors, improving overall survival. Table of Contents: • Epidemiology and etiology • Molecular biology and genetics • Diagnosis, staging and prognosis • Management • Research directions
Author: Toby A. Eyre
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318071609
Category : Medical
Languages : en
Pages : 80
Get Book Here
Book Description
Chronic lymphocytic leukemia (CLL) is the most diagnosed leukemia in the Western world, accounting for approximately 25% of all new leukemia diagnoses. In recent years, remarkable progress has been made in our understanding of both the pathophysiology and genetics of CLL. While the disease generally affects older adults and initially follows an indolent course, cytogenetic and molecular profiling have helped to predict clinical outcomes. Greater prognostication, alongside the development of an increasing armamentarium of novel targeted therapies, has enabled us to provide more personalized management options for patients. Table of Contents • Epidemiology and etiology • Molecular biology and genetics • Diagnosis, staging and prognosis • Management • Research directions
Author: E. Deconinck
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318068071
Category : Medical
Languages : en
Pages : 54
Get Book Here
Book Description
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare fast-growing hematodermic neoplasm that most often occurs in older men. It is notable for its highly aggressive behavior, with cutaneous, lymph node and bone marrow involvement. In the past, BPDCN has been poorly understood, recognized and treated, and consequently has had a poor prognosis. Today, it has been reclassified as a myeloid neoplasm and there is greater understanding of the disease’s clinical features, course and pathology, a new diagnostic test that makes prompt diagnosis possible and a new targeted therapy that, so far, has been shown to at least double survival. The complexity of caring for patients with BPDCN stems from both its rarity and its multiorgan involvement. 'Fast Facts: Blastic Plasmacytoid Dendritic Cell Neoplasm' is designed to bring hematologists, oncologists, dermatologists, pathologists, clinical nurse specialists and trainees in all these fields up to speed on the latest developments, as well as providing the most up-to-date information on first-line chemotherapy, consolidation treatments and stem cell transplantation. It will aid readers of all relevant medical disciplines to implement prompt diagnosis and effective management. Table of Contents: • What is BPDCN? Diagnosis • Management • Unmet needs and future directions
Author: Graham P. Collins
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318072869
Category : Medical
Languages : en
Pages : 188
Get Book Here
Book Description
Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.
Author: Kathryn Foucar
Publisher: Elsevier Health Sciences
ISBN: 0323879071
Category : Medical
Languages : en
Pages : 1005
Get Book Here
Book Description
This expert volume in the Diagnostic Pathology series is an excellent point-of-care resource for practitioners at all levels of experience and training. Covering the full range of nonneoplastic and neoplastic conditions of blood and bone marrow, it incorporates the most recent scientific and technical knowledge in the field to provide a comprehensive overview of all key issues relevant to today's practice. Richly illustrated and easy to use, the third edition of Diagnostic Pathology: Blood and Bone Marrow is a visually stunning, one-stop resource for every practicing pathologist, hematopathologist, oncologist, hematologist, resident, student, or fellow as an ideal day-to-day reference or as a reliable training resource. - Provides practicing pathologists with key details about new entities, newly recognized causes of morphologic change in blood and bone marrow abnormalities, and new strategies for appropriate workup of neoplastic processes—all with a focus on key tests and key differential diagnostic considerations - Helps pathologists recognize unique blood and bone marrow findings that can be an indicator for specific exposures, such as new medications, new targeted therapies, or toxins - Integrates updated technologies, newly recognized disorders, complications/features in blood and bone marrow, new targeted therapies, and the increased use of homeopathic remedies - Contains new chapters covering SARS-CoV-2 infection features in blood and bone marrow, myelodysplastic syndrome (MDS) mimics, blood and bone marrow findings linked to targeted therapies, blood and bone marrow findings linked to other medications, and more - Updates all existing chapters and contains expanded information on T-cell neoplasms in blood and bone marrow and intravascular large B-cell lymphoma in blood and bone marrow - Includes details from the World Health Organization (WHO) fifth edition Classification of Haematolymphoid Tumours and the very latest 2023 International Consensus Classification (ICC) publications, reflecting new and renamed diagnostic entities, tumor classification changes and updates, and terminology changes and updates - Discusses molecular testing strategies based on specific neoplasms and specific differential diagnostic consideration - Clearly delineates numerous genetic disorders often found in blood and bone marrow - Features more than 2,500 superb images, including histology and gross pathology photographs, full-color illustrations and graphics, clinical photographs and radiologic images, and many new tables and charts/algorithms - Employs consistently templated chapters, bulleted content, key facts, a variety of tables, annotated images, pertinent references, and an extensive index for quick, expert reference at the point of care - Includes the enhanced eBook version, which allows you to search all text, figures, and references on a variety of devices
Author: Raanani P Ed
Publisher: S. Karger AG (Switzerland)
ISBN: 9783805577731
Category : Blood
Languages : en
Pages : 0
Get Book Here
Book Description
Detection of minimal residual disease (MRD) is increasingly used in the management of leukemia patients. A wide variety of methods have been developed and include technologies designed to detect residual malignant cells beyond the sensitivity of conventional approaches such as morphology and banding cytogenetics in leukemia. The choice of the best method depends on the biology of the individual malignancy, i.e. on the determination of specific markers which are useful to differentiate between leukemic cells and normal hematopoiesis in leukemic patients. These markers include leukocyte differentiation antigens, fusion transcripts, transcripts overexpressed by mutated or nonmutated genes, rearranged genes, and individual markers like polymorphic repetitive DNA sequences. The major technologies for MRD detection, their advantages and disadvantages and their clinical applications are discussed in this special issue - from 'bench to bedside'. Providing a comprehensive overview on the significance of MRD in the evaluation, treatment and follow-up of hematologic malignancies, it will be of great value to hematologists, researchers interested in leukemias and lymphomas as well as laboratory technicians.
Author: Mohammad A. Vasef
Publisher: Elsevier Health Sciences
ISBN: 0443112800
Category : Medical
Languages : en
Pages : 1050
Get Book Here
Book Description
This expert volume in the Diagnostic Pathology series is an excellent point-of-care resource for practitioners at all levels of experience and training. Providing a clear understanding of molecular pathology as it relates to the transformation and pathogenesis of cancer in an era of personalized medicine, it incorporates the most recent scientific and technical knowledge in the field to provide a comprehensive overview of all key issues relevant to today's practice. Richly illustrated and easy to use, the third edition of Diagnostic Pathology: Molecular Oncology is a visually stunning, one-stop resource for every practicing pathologist, hematopathologist, molecular pathologist, oncologist, or pathologist in training as an ideal day-to-day reference or as a reliable learning resource. - Provides up-to-date, comprehensive coverage of relevant molecular tests and their clinical applications, along with organ-based chapters on the molecular genetic data relevant to individual disease entities - Contains new chapters and substantial revisions to existing content that include updates from the 2022 International Consensus Classification and the WHO Classification of Haematolymphoid Tumours, fifth edition - Provides expert guidance on selecting the right test(s) at the right time, as well as comparisons of molecular testing methods (e.g., FISH vs. cytogenetics) - Includes current information for new actionable mutations and targeted therapies - Covers ultrasensitive molecular techniques for minimal residual disease detection and disease monitoring - Discusses circulating cell-free DNA analysis for detection of resistance-associated mutations and disease monitoring, and provides usage details - Features an image-rich layout with more than 2,400 print and online-only images, including high-resolution H&E stains, immunostains, FISH images, gross pathology and clinical photographs, detailed full-color medical illustrations, and informative diagrams, charts, and schematics - Employs consistently templated chapters, bulleted content, key facts, a variety of tables, annotated images, pertinent references, and an extensive index for quick, expert reference at the point of care - Any additional digital ancillary content may publish up to 6 weeks following the publication date
